XBiotech (STU:4XB) Valuation Rank


STU:4XB XBiotech Inc STU:4XB
38 GF Score
Price €2.00
GF Value €0.15
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is XBiotech Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

XBiotech Valuation Rank Related Terms

STU:4XB
38GF Score
XBiotech Inc STU:4XB
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is XBiotech (STU:4XB) Overvalued in 2026?

Based on GuruFocus' analysis, XBiotech stock appears to be overvalued. The current stock price of €2.00 is trading 1233.3% above its estimated GF Value™ of €0.15. GuruFocus considers XBiotech to be Significantly Overvalued.

Key valuation signals for STU:4XB:

  • Valuation Rank:
  • GF Value™: €0.15 vs. price of €2.00 (1233.3% above fair value)
  • GF Score™: 38/100 with 2 warning signs

No single metric tells the full story. See the STU:4XB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

XBiotech Business Description

Other Exchanges XBIT:USA
Address 5217 Winnebago Lane, Austin, TX, USA, 78744
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
38GF Score

Get the complete analysis for STU:4XB

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.00
Price
€0.15
GF Value